Mind Medicine has linked its psychedelic medicine to improvements in patients with generalized anxiety disorder. After one hit of lysergide d-tartrate, a hallucinogen better known as LSD, patients in ...

MindMed announced that the FDA has granted breakthrough designation to its MM120 program for the treatment of generalized anxiety disorder. MindMed also announced the pricing of an underwritten ...

The FDA's decision on MDMA therapy for PTSD is imminent, impacting MindMed investors and the psychedelic medicine industry. An FDA advisory committee voted against approving MDMA therapy, causing ...

Mind Medicine (MindMed) Inc. (MNMD) is a biotech that should be on everyone's watch list. The reason why I state this is that it has been able to make substantial improvements in the MDMA treatment ...

-A single oral administration of MM120 100 µg met its key secondary endpoint and maintained a clinically and statistically significant HAM-A reductions compared to placebo at 12 weeks with a 65% ...

MindMed’s MNMD Phase 2b clinical trial on proprietary LSD compound MM-120 targeting Generalized Anxiety Disorder (GAD) is over 50% enrolled and dosed. “We have seen a meaningful acceleration in ...

Mind Medicine (MindMed) MNMD is developing its lead pipeline candidate, MM120, an orally disintegrating tablet (ODT) and a pharmaceutically optimized form of lysergide D-tartrate (LSD), for the ...

Biotech company MindMed is shoring up its cash stockpile to inch its psychedelic therapies towards approval after the feds’ recent thumbs-down of using MDMA to treat post-traumatic stress disorder.

MindMed MNMD announced significant progress in the phase IIb study of its lead candidate MM-120 (lysergide D-tartrate) for anxiety disorder. The study has already enrolled and dosed more than 50% of ...

The stock of psychedelics company Mind Medicine Inc. MNMD rose 4% Friday, after the company’s Swiss research partners reported positive results from a Phase 2 trial of LSD as a treatment for major ...